The expression of many cellular genes is modulated by DNA methylation and histone acetylation. These processes can influence malignant cell transformation and are also responsible for the silencing of DNA constructs introduced into mammalian cells for therapeutic or research purposes. As a better understanding of these biological processes may contribute to the development of novel cancer treatments and to study the complex mechanisms regulating gene silencing, we established a cellular system suitable to dissect the mechanisms regulating DNA methylation and histone acetylation. For this purpose, we stably transfected the neuroblastoma cell line U87 with a cytomegalovirus promoter-driven reporter gene construct whose expression was analyzed following treatment with DNA methylation inhibitor 5'-aza-2`deoxycytidine or histone deacetylation inhibitor trichostatin A. Both substances reactivated the silenced cytomegalovirus promoter, but with different reaction kinetics. Furthermore, whereas trichostatin A reactivation kinetic did not substantially change over the time range considered (five days), reactivation sustained by 5'-aza-2`deoxycytidine showed profound differences between day one and longer time points. We showed that this effect is related to the down regulation of DNA replication by 5'-aza-2`deoxycytidine. Finally, we proved that the simultaneous administration of trichostatin A and 5'-aza-2`deoxycytidine resulted in the reactivation of the CMV promoter according to a cooperative but not synergistic or additive mechanism. In conclusion, our cellular system should represent a powerful tool to investigate the complex mechanisms regulating gene silencing and to identify new anti-cancer drugs.
ABSTRACT
The expression of many cellular genes is modulated by DNA methylation and histone acetylation. These processes can influence malignant cell transformation and are also responsible for the silencing of DNA constructs introduced into mammalian cells for therapeutic or research purposes. As a better understanding of these biological processes may contribute to the development of novel cancer treatments and to study the complex mechanisms regulating gene silencing, we established a cellular system suitable to dissect the mechanisms regulating DNA methylation and histone acetylation. For this purpose, we stably transfected the neuroblastoma cell line U87 with a cytomegalovirus promoter-driven reporter gene construct whose expression was analyzed following treatment with DNA methylation inhibitor 5'-aza-2`deoxycytidine or histone deacetylation inhibitor trichostatin A. Both substances reactivated the silenced cytomegalovirus promoter, but with different reaction kinetics. Furthermore, whereas trichostatin A reactivation kinetic did not substantially change over the time range considered (five days), reactivation sustained by 5'-aza-2`deoxycytidine showed profound differences between day one and longer time points. We showed that this effect is related to the down regulation of DNA replication by 5'-aza-2`deoxycytidine. Finally, we proved that the simultaneous administration of trichostatin A and 5'-aza-2`deoxycytidine resulted in the reactivation of the CMV promoter according to a cooperative but not synergistic or additive mechanism. In conclusion, our cellular system should represent a powerful tool to investigate the complex mechanisms regulating gene silencing and to identify new anti-cancer drugs. 4 in histone hyperacetylation. This last event is responsible for a more relaxed chromatin conformation which allows for the binding of transcription factors to promoters with the consequential changes in gene expression.
INTRODUCTION
The cellular model we chose to test the effects of 5'-AZA and TSA on promoter reactivation is based on a stable transfectant of the human glioblastoma cell line U87, which was engineered to express a fusion protein of hygromycin and enhanced green fluorescence protein (H-EGFP) under control of the CMV promoter. In the presence of hygromycin B, cells are selected for expression of the fusion protein which can be visualised by fluorescence microscopy and quantified by flow cytometry. Removal of selection pressure leads to down-regulation of CMV promoter activity within a few days. As the green fluorescence of the cells is proportional to CMV promoter dependent expression rate, it is possible to follow fluctuations in promoter activity by quantifying fluorescence intensities. In U87 cells we show that upon removal of selection pressure and down-regulation of CMV promoter activity, it is feasible to rescue its activity by application of TSA and 5'-AZA, which induce reactivation with different kinetics. Furthermore, we show that whereas the TSA reactivation kinetic does not substantially change over the time range considered here (five days), reactivation sustained by 5'-AZA displays profound differences between day one and longer time points. We provide evidence that this effect is related to the down regulation of DNA replication induced by 5'-AZA. Finally, we demonstrate that the simultaneous administration of TSA and 5'-AZA results in the reactivation of the CMV promoter according to a cooperative, but not synergistic mechanism at all concentrations of TSA and 5'-AZA tested.
MATERIALS AND METHODS

Construction of plasmid pCMV-HygroEGFP
Vector pCRScript SK(+) (Stratagene) was opened with EcoRV and HindIII, a 625 bp SmaI/HindIII fragment containing the polyadenylation signal of the herpes simplex virus thymidinkinase was ligated into the vector, giving rise to the intermediate construct pScriptpolyA. All further cloning steps were performed following blunt end generation with T4 DNA polymerase of the respective fragments and vectors. The 620 bp PstI CMV promoter fragment of plasmid pL15TK (28) was ligated into the SrfI site of pScriptpolyA (pCMV-A). This plasmid was opened with PstI, and the BamHI/NotI EGFP fragment of plasmid pEGFP (Clontech) was ligated into this site (pCMV-EGFP). A 1031 bp PCR fragment comprising the open reading frame of the hygromycin resistance gene without stop codon was ligated into the AgeI site of pCMV-EGFP and sequenced, resulting in the desired plasmid pCMV-HygroEGFP containing an in frame fusion of hygromycin and EGFP, separated by short peptide linker (pro-val-ala-thr).
Cell lines
U87 cells (ATCC catalogue number: HTB-14) were stably transfected with plasmid pCMV-HygroEGFP using the calcium phosphate transfection protocol. Colonies resistant to 800 U/ml hygromycin B were selected and subjected to subcloning. One clone, U87 H-EGFP, was identified by fluorescence microscopy which stably expressed the fusion protein in 100 % of cells in the presence of hygromycin, the selection agent. Without hygromycin, the expression of hygromycin-EGFP fusion protein rapidly decreased within two days. U87 H-EGFP and U87 parental cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM low glucose, Gibco, BRL) supplemented with 10% foetal calf serum (Seromed), 100 units/ml of penicillin, 100 µg/ml of streptomycin and 1 µg/ml amphotericin B (Gibco, BRL), at 37°C in humidified atmosphere containing 5% CO 2 . Culture medium was supplemented with 800 units/ml of hygromycin B (Calbiochem) for the U87 H-EGFP cell line.
Fluorescence microscopy
About 10
5 U87 H-EGFP and U87 parental cells were seeded on polylysine-coated cover slips. Cells were treated with 5'-aza-2`deoxycytidine (5'-AZA, Sigma) and trichostatin A (TSA, Sigma) for 48 h and then fixed in 5% formaldehyde/PBS for 30 min at room temperature. Afterwards, samples were analyzed by fluorescence microscopy (Axiophot, Zeiss, Germany).
Flow cytometry
U87 H-EGFP and U87 parental cells were seeded at a density of 1.5 x 10 5 cells per well in six-well plates (Nuclon, NUNC) using DMEM without hygromycin B. Forty eight hours later, cells were exposed to either 5'-AZA or TSA (Sigma) for different time intervals, ranging from one up to five days. Afterwards, cells were trypsinized, resuspended in 1 ml of complete DMEM and stained by propidium iodide with a final concentration of 10 µg/ml. Cells were then re-suspended in phosphate buffered saline (PBS, NaCl 0.1369 M, KCl 0.0026 M, Na 2 HPO 4 0.0103 M, KH 2 PO 4 0.0017 M, pH 7.4), and individual cells were analyzed by flow cytometry (FACScalibur instrument, Becton Dickinson). Data were analyzed by CELLQUEST software. Dead cells, i.e. positive for propidium iodide staining only, were excluded from the evaluation of fluorescence intensity. The median of fluorescence intensity (MFI) was used to define the fluorescence intensity of each cell population analyzed.
Evaluation of DNA replication
U87 H-EGFP cells were cultured as described in the section 'flow cytometry' and treated with either 1 µM 5'-AZA, 40 µM 5'-AZA or remained non-treated. One or five days thereafter, cells were pulsed with BromodeoxyUridine (BrdU) (final concentration 10 µM) for 8 hours and then prepared as follows. Cells were harvested, centrifuged for 5 min. at 500xg and fixed in ice-cold 70 % ethanol for 20 min. After adding 1x PBS containing 0.5 % bovine serum albumin (wash buffer), cells were pelletted for 5 min at 500xg, then re-suspended in 1M HCl, 0.5 X PBS, 0.5% bovine serum albumin (denaturing solution). After twenty minutes, cells were washed with wash buffer, resuspended in 0.1M sodium borate (Na 2 B 4 O 7 ), pH 8.5, for 2 min. Following a last wash, each sample was divided into two aliquots: one was incubated with an anti-BrdU monoclonal antibody (Becton Dickinson) while the other one was incubated with an isotype antibody (Becton Dickinson) which does not bind to BrdU. Both incubations were performed for 40 min. After a washing step, pellets were incubated for 1 hour in the presence of RNAse A (final concentration 100 µg/ml) and 7-amino-actinomycin D (Via-PROBE, Becton Dickinson) in the dark. Finally, each sample was washed with wash buffer, re-suspended in 1 X PBS, and analyzed by flow cytometry using a FACScalibur (Becton Dickinson, Mountain View, CA). Data were analyzed with CELLQUEST software.
Mathematical description of CMV promoter reactivation
To mathematically describe the correlation between MFI, which reflects the degree of promoter reactivation, and the concentration of the reactivating agent, we developed the two equations described below.
For the relations between MFI and the concentration C of 5'-AZA, we found the following empirical exponential law: ). Due to the scattering characteristic of the data in the case of TSA we were obliged to recur to the following more complex empirical law: For both equations, it can be mathematically demonstrated that, with the increase of C values, MFI tends to a plateau situated at A+B. This indicates that, when C approaches a threshold value (in our experimental set up 40 µM 5'-AZA or 3 µM TSA), any further increases of C will not modify MFI, as seen in our experiments. On the contrary, when C approaches zero, MFI tends to A, which represents the background fluorescence of the cells.
Sodium bisulfite conversion
DNA was extracted from cell cultures by the salting out method and modified by the sodium bisulphite technique as reported (29) , with some modifications. Briefly, 3 µg of genomic DNA was denatured by a freshly prepared 0.37 M NaOH solution for 15 minutes at 75°C. DNA was then treated with sodium bisulphite at 3.6 M final concentration adjusted to pH 5.0 and 1 mM hydroquinone, overlaid with mineral oil and incubated at 55°C for 6 h. DNA samples were purified by Wizard DNA Clean-Up System according to the manufacturer (Promega). Modification was completed by desulphonation, incubating samples with 0.3 M NaOH for 15 minutes a 37°C. The solution was neutralised by addition of NH4Oac, pH 7 to 3M and the DNA was ethanol precipitated.
PCR amplification and sequencing of the CMV promoter
After ethanol precipitation, DNA samples were solved in 20µl of 10mM Tris/Cl pH 8 solution. A fragment of 360 bp of the CMV promoter containing 15 CpG sites was amplified by PCR. Primers were designed to amplify bisulfite converted DNA. Amplifications were performed in 100 µl reaction mixture containing 4 µl of bisulphitetreated genomic DNA, 200 µΜ dNTPs, 0.4 µM primers, 50 mM KCl, 1.5 mM MgCl 2, 10 mM Tris-HCl pH 9, 5% DMSO, 0.2 µl Taq DNA polymerase (Promega). Primers used were: 1F: ATTATTGACTAGTTATTAATAGTAATCA (positions 145-172 of GenBank sequence AF477200) and 1R: TAAATATACTACCAAATAAAAAAATCC (positions 492-466) under the following conditions: 94°C/30 sec, 52°C/60 sec, 72°C/30 sec for 35 cycles. PCR fragments were purified using the microspin S-400 spin column. Nucleotide sequencing was performed by an automatic sequencer using both forward and reverse primers. The diagrams are derived directly from sequence electropherograms. Each column has been calculated from the ratio between the height of thymine electropherogram peak in that site and the sum of heights of cytosine and thymine peaks in the same site.
Statistical analysis P values were calculated using the Anova one-factorial variance analysis program led by MS Excel. P values < 0.05 were considered to be statistically significant. 
RESULTS
Establishment of U87 H-EGFP cell line
The model system presented here was obtained by stable transfection of the human glioblastoma cell line U87 with plasmid pCMVhygroEGFP. Under the control of the CMV promoter, this plasmid expresses fusion of the hygromycin resistance gene and the enhanced green fluorescence gene (H-EGFP). The fusion protein H-EGFP renders cells resistant to the antibiotic hygromycin B, which thus allows for the selection of stable transfectants. Due to the EGFP portion of the fusion protein, cells expressing this gene can easily be detected by fluorescence microscopy and flow cytometry. In the absence of the selective agent hygromycin, cells rapidly down regulate the expression of H-EGFP, as evidenced by the rapid loss of green fluorescence, indicating that CMV promoter activity is directly proportional to the amount of H-EGFP protein present in the cells. Thus, we could investigate promoter activity by flow cytometry without further RNA analysis.
Effects of 5'-AZA on CMV promoter activity
To study the mechanisms regulating gene silencing and to investigate whether CMV promoter activity can be rescued and/or modulated in our system, 5'-AZA, a drug known to interfere with the process of gene silencing (27) , was applied to U87 H-EGFP cells. Cells were cultured in the absence of hygromycin B for two days, so that silencing of the CMV promoter could occur. This time point was chosen as longer culturing in the absence of selective pressure did not substantially decrease CMV expression. Afterwards, cells were incubated for different time intervals from one up to five days, in the presence of different concentrations of 5'-AZA. To quantify the effects of 5'-AZA on the degree of CMV promoter activity, as visualized by green fluorescence, flow cytometry was conducted on treated cells. A representative example of the experiment performed is shown in Figure 1 A together with the corresponding fluorescence microscopy image. Figure 1B -D summarizes the results with the median fluorescence intensity (MFI), reflecting CMV promoter reactivation, plotted against the amount of 5'-AZA administered. At day one ( Figure  1B ) an inverse correlation between MFI and 5'-AZA concentration was detected. On the contrary, both at day 2 and 5 ( Figure 1C and D) a direct correlation between the concentration of 5'-AZA and MFI was observed. We speculated that the inverse correlation noticed at day one could have due to a 5'-AZA-mediated inhibitory effect on DNA replication, which would have reduced 5'-AZA incorporation into DNA thus affecting its demethylating activity and CMV promoter reactivation. At longer time points, the replication inhibitory effect could have been relieved with the consequent increase of DNA replication rate and reactivation of CMV promoter. To prove our hypothesis, DNA replication rates were evaluated, by means of BromodeoxyUridine (BrdU) incorporation, in cells treated with either 1 or 40 µM 5'-AZA at day one and five. These time points and 5'-AZA concentrations were chosen as most evident were the differences with respect to CMV promoter reactivation. Because of the inhibitory effect of 5'-AZA on DNA replication at day one, which affects CMV promoter expression, CMV promoter reactivation kinetic was studied at longer time points. Therefore, we focused our attention on day two where a direct correlation between the concentration and MFI increase was evident and where a minor effect on DNA replication was revealed (data not shown). Day five was excluded as the clear reduction in MFI indicated that the effects of 5'-AZA was almost relieved, thus making a kinetic analysis not appropriate. For a comprehensive evaluation of the reactivation kinetic at day two, additional concentrations of 5'-AZA were tested as shown in Figure 3 . In these set of experiments, we included also the parental cells U87 which do not contain the pCMVhygroEGFP plasmid, in order the prove that 5'-AZA per se does not induce any fluorescence increase, independent of the expression of H-EGFP fusion protein. At 1 µM 5'-AZA, U87 H-EGFP showed a 1.5 fold increase in MFI (Figure 3 ) compared to non-treated U87 H-EGFP (p = 0.0055). Furthermore, MFI increased progressively with the increase of 5'-AZA concentrations reaching a maximum at 40 µM (2.1-fold increase, compared to non-treated U87 H-EGFP). Parental U87 cells, which do not contain the plasmid pCMVhygroEGFP, showed a negligible increase in MFI (Figure 3 ) compared to non-treated U87.
Effects of TSA on CMV promoter activity CMV promoter reactivation was also studied in the presence of TSA, a drug known to interfere with the process of gene silencing (5), by acting on histone acetylation status. As for 5'-AZA studies, different concentrations of TSA were applied to U87 H-EGFP cells for different times, from one up to five days. A representative example of the experiment performed is shown in Figure 4 A together with the corresponding fluorescence microscopy image. The results, summarized in Figure 4B -D, are expressed as MFI, reflecting CMV promoter reactivation, plotted against the amount of TSA administered. At all time points considered, a direct relation between MFI and TSA concentration was noticed. At day one, however, a saturation of CMV promoter reactivation was detected already at 1 µM TSA. Additionally, a marked reduction in the absolute values of MFI was evident at day five compared to days one and two, indicating an extinction of TSA effect, similarly to what shown for 5'-AZA. Therefore, in analogy to 5'-AZA experiments, for a more detailed characterization of CMV promoter reactivation kinetic, we chose day two. As done for 5'-AZA treated cells, parental cell line U87, which do not contain the pCMVhygroEGFP plasmid, were included, in order the prove that TSA per se does not induce any fluorescence increase, independent of the expression of H-EGFP fusion protein. At 200 nM TSA, U87-H-EGFP ( Figure 5 ) showed a significant increase (p = 5.8x10 -6 ) of 1.5 folds in MFI compared to non-treated U87 H-EGFP. At 1 and 3 µM TSA 3.9 and 5.8-fold increases were observed. As in the case of 5'-AZA treatment, in the parental cell line U87, which does not contain the plasmid pCMVhygroEGFP, a negligible increase in MFI, compared to non treated U87, was detected. Finally, whereas the effects on cell proliferation of 5'-AZA depended on the drug concentration and the administration time, in the case of TSA a clear inhibition of cell proliferation was noticed all the conditions tested (data not shown). Methods) in order to precisely characterize the reactivation kinetics of 5'-AZA and TSA. Figure 6 shows both the experimental data obtained and the data fitting by our mathematical descriptions of CMV promoter reactivation in the presence of 5'-AZA and TSA. The relevant difference between equations I and II (see Materials and Methods) is given by the value of the C exponent, n, which is equal to 1 and 2.48 in the case of equation I (5'-AZA) and equation II (TSA), respectively. From a mathematical point of view this indicates that CMV promoter reactivation induced by 5'-AZA follows a normal exponential law, while reactivation induced by TSA follows a so called "stretched exponential" and not a pure exponential law. Thus, it can be concluded that the two chemicals have different reaction kinetics. Despite of this difference, for both equations, the mathematical analysis predicts that when C approaches a threshold value, a plateau level for MFI is reached and any further increase of C will not result in any substantial increase of MFI. This is exactly what we see at the experimental level in the case of 5'-AZA and TSA treatment (Figure 3 and 5) , providing the accuracy of the mathematical description of the experimental data.
Effect of a combined administration of 5'-AZA and TSA
After demonstrating the dose-dependent reactivation of the CMV promoter by 5'-AZA and TSA in our system, we investigated the combined effect of these two chemicals on the rescue of CMV promoter activity. For a comprehensive characterization of the possible interaction between the two drugs in our model, different concentrations of 5'-AZA and TSA were administered simultaneously to U87 H-EGFP cells. For this purpose, we studied the combined effects of: i) the minimal concentration of 5'-AZA (1µM) and TSA (0,2µM) able to induce a significant increase in MFI compared to non treated cells, ii) a concentration of 5'-AZA (5µM) and TSA (1µM) able to induce an intermediate increase of MFI, and iii) the concentration of 5'-AZA (40µM) and TSA (3µM) which resulted in a saturation of MFI increase. For each of the combination tested, the effects on MFI were compared to those induced by the separate administration of each of the two drugs. As shown in Figure 7 , the simultaneous administration of 1 µM 5'-AZA and 0.2 µM TSA resulted in a significant, although modest, increase (p < 0.05) in MFI, compared to cells treated with each of the two agents alone. Similar results were obtained treating cells with either 5µM 5'-AZA and 1µM TSA or 40µM 5'-AZA and 3µM TSA. Notably, in all cases, the simultaneous administration of the two drugs increased MFI modestly, neither resulting in a synergistic nor in an additive reactivation of the CMV promoter.
Evaluation of the CMV promoter methylation status
It is well known that DNA methylation blocks the access of transcription factors to gene promoters and is involved in the mechanisms which leads to histone deacethylation, thus preventing gene expression. To prove that this mechanism was responsible also in our cellular model for CMV promoter silencing, the methylation status of 15 CpG sites in the promoter region were analysed under different experimental conditions. As shown in Figure 8 , the methylation grade of single CpG sites of the untreated cultures and of 5'-AZA or TSA treated ones are directly compared. The overall result indicates that about one half of the sites are methylated in untreated culture. However not a single site is completed methylated confirming the extreme variability of the methylation process. As expected, treatment with 5'-AZA strongly inhibits the methylation process, although residual methylation is present. Finally, a reduction of the methylation status is not observed in cultures treated with TSA, as expected.
DISCUSSION
DNA methylation/de-methylation and histone acetylation/de-acetylation processes play an important role in controlling endogenous gene expression both during (16;17) and after development (18) (19) (20) (21) (22) (23) . We have taken advantage of the fact that these phenomenon also regulate the expression of exogenous DNA transcription units, to generate a cellular model which offers the possibility to study the complex mechanism regulating DNA methylation and histone acetylation status. Our system is based a stable transfectant of the human glioblastoma cell line U87, which was engineered to express a fusion protein of hygromycin and enhanced green fluorescence protein (H-EGFP) under control of the CMV promoter. CMV promoter activity was evaluated in the presence and in the absence of 5´-AZA and TSA, two inhibitors of DNA methylation and histone deacetylation, respectively.
For a detailed characterization of 5'-AZA and TSA mediated reactivation of the CMV promoter we investigated the effects of these drugs over a time period of five days, which represents the upper limit for the proper detection of MFI variation in our system. Whereas TSA did not show any relevant differences in the reactivation trend over time (Figure 4 ), 5'-AZA did. In particular, an opposite behavior of the reactivation kinetic was noticed at day one compared to days two and five (Figure 1) . At day one, indeed, an inverse correlation between MFI and 5'-AZA concentration was detected ( Figure 1B) . We demonstrated that this phenomenon is related to the inhibition of DNA replication, moderate at low 5'-AZA concentration (Figure 2A, 1µM ) and severe at higher concentration (Figure 2A , 40µM 5'-AZA). We think that the impairment of DNA replication reduces 5'-AZA incorporation into DNA thus interfering with its demethylating activity and therefore affecting CMV promoter reactivation. The mechanism through which 5'-AZA induced DNA replication inhibition may depend on the interference with cellular metabolic pathways, such as the de novo thymidylate synthesis, known to be affected by the enzymatic deamination of 5'-AZA (30) . Additionally, as replication is not completely shut down, it is also possible that the inhibitory effect is mediated by the toxicity induced by the covalent link between DMNTs and the 5'-AZA incorporated into the DNA, as shown in other systems (27) .
The marked reduction over time of 5'-AZA mediated DNA inhibition (see Figure  2B ), rendered days two and five appropriate to evaluate CMV promoter reactivation. However, day five was excluded due to the clear MFI reduction (compare Figure 1C  with 1D ), indicative of a cessation of 5'-AZA effect. For the same reason, also in the case of TSA, day two was preferred to day five. Our data show that for both 5'-AZA and TSA, CMV promoter rescue occurs in a dose-dependent manner (Figures 3 and 5) . However, reactivation kinetic differs for the two agents as indicated by the mathematical interpretation of the experimental data ( Figure 6 A and B) . In particular, whereas 5'-AZA reactivation follows a normal exponential law, TSA reactivation follows a so called "stretched exponential" law. The mathematical system presented here can be used to describe the reactivation behavior of the CMV promoter as well as those of other promoters in other cell lines, allowing a rigorous comparison between different experimental conditions. When applied to other experimental settings, this approach should be useful to rule out whether and how the reactivation kinetics of 5'-AZA and TSA differ among different promoters and cell lines providing new insights in DNA methylation and histone acetylation, two relevant biological processes altered in many cancer cells.
The mathematical analysis described above indicates that the TSA effect occurs over a narrower concentration range and follows a more sigmoidal curve (active concentration range 0.2-3 µM, Figures 5 and 6B ) compared to that of 5'-AZA (active concentration range 1-40 µM, Figures 3 and 6A) . Although several factors can account for the differences in TSA and 5'-AZA mediated reactivation of the CMV promoter, a possible explanation may reside in the fact that TSA prevents transcription by directly inhibiting deacetylation whereas 5'-AZA exerts its action in a more complex way. It acts directly preventing the recruitment of MBD proteins, thus allowing the transcription machinery to bind to the promoter, and indirectly, preventing HDACs recruitment to the gene promoter, thus inducing histone hyperacetylation and consequently activation of transcription. It is therefore possible that the reaction kinetic shown by 5'-AZA results from the combination of these two mechanisms, thus explaining the different kinetic compared to TSA.
To further investigate the influence of 5'-AZA and TSA on CMV promoter reactivation in our cellular system, the combined effect of the two drugs was tested. As shown in Figure 7 , we could detect a significant increase (p<0.05) of MFI in cells treated with a combination of the two drugs, regardless of the concentration of each of them, compared to the cells treated with one drug only. The modest increase in MFI indicates that a co-operative rather than an additive or a synergistic effect takes place under our experimental conditions. These data are in contrast with the synergistic effects described for 5'-AZA and TSA in a previous work by Cameron et al. (35) . This discrepancy may be due to the fact that different cell lines were used, i.e. the U87 neuroblastoma cell lines in the present work and the RKO colorectal carcinoma cells in Cameron's work. It is possible that U87 and RKO cells contain different amounts of each of the three classes of HDACs (4) resulting in a different behavior in the presence of an HDACs inhibitor. For example, as HDAC class III is insensitive to TSA (35;36), a prevalence of this class of enzyme over the other two in our cell line, would influence the overall effect of TSA. Furthermore, the acetylation status of promoters depends not only on HDACs but also on HATs. Given the several different families of HATs (4), it is possible that a different distribution of these families of enzymes among cell lines affects acetylating capacity accordingly. A second major difference in the experimental set up between our and Cameron's system, resides in the different promoters used, i.e. CMV promoter and MLH1 and TIMP3 promoters, respectively. In this regard, it is well conceivable that HDACs and HATs, regulating histone acetylation status, and DNMT, regulating DNA methylation, may act differently on different promoters.
The data describing the effects of 5'-AZA and TSA on CMV promoter reactivation have been generated from one clone of U87 cells stably containing the H-EGFP gene. Therefore, in principle, we cannot totally exclude the influence of a clonal effect on these results. However, at least two observations indicate that the U87 H-EGFP cell clone does not substantially differ from the parental U87 cell line, thus conferring to our results a general value. First, we have evidence (data not shown) that the U87 H-EGFP cell clone behaves similarly to the parental U87 cells in terms of proliferation and cell cycle phase distribution. Secondly, the effects of 5'-AZA and TSA on cell proliferation (data not shown) are absolutely comparable between U87 and U87 H-EGFP cells, indicating comparable transcriptional effects on genes regulating cell cycle.
While 5'-AZA showed a reversible inhibition on cell proliferation (Figure 2A -B), TSA strongly inhibited U87 H-EGFP cell growth at all the concentrations and time points tested (data not shown). Since U87 cells originated from a human neuroblastoma, these observations indicate that TSA might be of therapeutic benefit for the treatment of neuroblastoma, the most common extra-cranial solid tumor in pediatric age (39) . Although our data should be confirmed in primary tumor cells freshly isolated from patients, they corroborate the usefulness of HDACs inhibitors in the treatment of neuroblastoma (40) and in general, the effectiveness of TSA in preventing the growth of different tumor cells (32;33;41-43) .
The data presented here are based on the concept that in our cellular model CMV promoter silencing is due to methylation, as reported in other cellular systems (see for review 7, 8, 9) . To show that this is the case also in our system and to prove its validity, the methylation pattern of CMV promoter was evaluated. Our data show (Figure 8 ) a reduction of about 60% in the number of methylated sites in 5'-AZA treated cells compared to non treated cells, thus confirming the mechanism of action of 5'-AZA and the relevance of methylation as expression inhibition mechanism in our cell system. Notably, these sites are not hundred percent in non-treated cells. This is not surprising as we have shown that a residual expression is detectable (Figure 3 ) in non-treated U87 H-EGFP cells compared to U87 cells, compatible with a partial promoter methylation. As expected, TSA treatment did not alter the percent of methylated sites in comparison to non treated cells, confirming the knowledge about its mechanism of action (35) . The fact that TSA induced CMV promoter reactivation in the context of a partially methylated promoter supports the observation that decreased methylation is a prerequisite for effective transcription following histone acetylation (35) . This, as well as other aspects about the mechanism of gene silencing, can be further investigated using our model, thus showing its potential as investigational tool. Additionally, our system can be used to characterise the effects of a variety of DNA methylation and histone deacetylation inhibitory agents such as 5-methylcyosine analogues (7), butyrate, valproic acid, or pyroxamide (4), respectively. Moreover, our system is suitable to study other processes regulating promoter activation such as histone phosphorylation and methylation (2) and, in general, the complex mechanisms regulating gene silencing. Finally, the fact that promoter reactivation can be studied by simply measuring variations in the green fluorescence intensity of the cells, without the need to perform procedures such as mRNA extraction, Northern blot, and quantitative RT-PCR, makes our model fast and economically advantageous.
In summary, we have shown that treatment of cells with the drugs 5'-AZA and TSA, known to inhibit DNA methylation and histone deacetylation, respectively, can rescue CMV promoter activity with different kinetics and that simultaneous inhibition of these two mechanisms results in a co-operative reactivation. The lack of a synergistic effect between 5'-AZA and TSA, as described for other cell lines, suggests a cell-type specific role for DNA methylation and histone deacetylation in the regulation of gene expression. Finally, the cell system presented here should be useful to expand the knowledge on the mechanisms regulating gene expression and to identify and characterize new anti-cancer drugs. 
ACKNOWLEDGMENTS
